Photo of Judith Aberg

Judith Aberg

  • SENIOR FACULTY Medicine, Infectious Diseases
Print ProfilePrint Profile

Specialty

Certifications

  • Infectious Disease

Education

  • MD, Penn State College of Medicine

  • Residency, Internal Medicine
    Cleveland Clinic Hospital

  • Fellowship, Infectious Disease
    Washington University Medical Center

Biography

    Judith A. Aberg, MD
    Dr. George Baehr Professor of Clinical Medicine

    A nationally-renowned researcher in the field of HIV and AIDS, Dr. Aberg has been instrumental in developing national, state, and local guidelines for HIV prevention and the care of HIV-infected persons. Her reputation as a scientific leader has been well established herself through her ongoing clinical research activities in HIV-related opportunistic infections, vaccine response, and complications of HIV disease, including studies of the pathogenesis of inflammation that contributes to the co-morbidities associated with the aging of those with HIV infection.

    Dr. Aberg, who was recruited to the Icahn School of Medicine at Mount Sinai earlier this year, serves as Chief of the Division of Infectious Diseases and Immunology and Director of the Infectious Diseases Clinical and Translational Research Center.

    A thought leader in the study of infectious diseases, Dr. Aberg is a highly sought-after speaker and frequently lectures at international and national HIV/AIDS conferences, symposia, and workshops.  Dr. Aberg serves on panels for the New York State Department of Health, the International AIDS Society-USA, and the Department of Health and Human Services. She was also Chair of the HIV Medicine Association (HIVMA), an organization representing more than 5,000 HIV providers advocating for policies to ensure a comprehensive response to the AIDS pandemic informed by science and social justice. This past year she was elected as the HIVMA representative to the Infectious Disease Society of America’s Board of Directors.

    Dr. Aberg is the author of more than 100 peer-reviewed publications and has participated in more than 100 clinical trials.  She is Co-Editor-in-Chief for HIV Clinical Trials, serves on the editorial board for two infectious disease journals, and is an ad hoc reviewer for more than 15 journals.

    Dr. Aberg earned her medical degree from Pennsylvania State University.  She completed her internal medicine residency and chief resident year at the Cleveland Clinic before going on to complete an Infectious Disease fellowship at the Washington University School of Medicine.  Prior to joining Mount Sinai, Dr. Aberg was Director of Infectious Diseases and Immunology and the Jeffrey Bergstein Professor of Medicine at New York University School of Medicine and the Director of Virology at Bellevue Hospital Center, positions she had held since joining the NYU faculty in 2004.  Previously, she served as Assistant Professor and Co-Director of the AIDS Clinical Trial Unit at the University of California, San Francisco and later as Associate Professor and Director of HIV Services at Washington University.

Publications

Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA, Infectious Diseases Society of America . Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014 Jan; 58(1).

Mercer F, Khaitan A, Kozhaya L, Aberg JA, Unutmaz D. Differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors. Journal of immunology (Baltimore, Md. : 1950) 2014 Aug; 193(3).

Cespedes MS, Castor D, Ford SL, Lee D, Lou Y, Pakes GE, Aberg JA. Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. Journal of acquired immune deficiency syndromes (1999) 2013 Apr; 62(5).

Cespedes MS, Kerns SL, Holzman RS, McLaren PJ, Ostrer H, Aberg JA. Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268. HIV clinical trials; 14(6).

O'Brien M, Montenont E, Hu L, Nardi MA, Valdes V, Merolla M, Gettenberg G, Cavanagh K, Aberg JA, Bhardwaj N, Berger JS. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. Journal of acquired immune deficiency syndromes (1999) 2013 Jul; 63(3).

Wolff MJ, Poles MA, Aberg JA. Clash of the microbes: let's bring back the good guys. The Journal of clinical investigation 2013 Feb; 123(2).

Aberg JA, Tebas P, Overton ET, Gupta SK, Sax PE, Landay A, Falcon R, Ryan R, De La Rosa G. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS research and human retroviruses 2012 Oct; 28(10).

Aberg JA. Aging, inflammation, and HIV infection. Topics in antiviral medicine; 20(3).

Doshi S, Chen TF, Zapata J, Holzman RS, Zapata LC, Aberg JA, Sivapalasingam S. Risk factors for tuberculin skin test conversion among HIV-infected patients in New York City. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2012 Jul; 16(7).

Doshi S, Chen TF, Zapata J, Holzman RS, Zapata LC, Aberg JA, Sivapalasingam S. Risk factors for tuberculin skin test conversion among HIV-infected patients in New York City. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2012 Jul; 16(7).

Eckhardt BJ, Holzman RS, Kwan CK, Baghdadi J, Aberg JA. Glycated Hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals. AIDS patient care and STDs 2012 Apr; 26(4).

Kwan CK, Eckhardt B, Baghdadi J, Aberg JA. Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York. AIDS research and human retroviruses 2012 Sep; 28(9).

Danoff A, Daskalakis D, Aberg JA. Care for transgender persons. JAMA 2013 May; 309(20).

Danoff A, Horberg M, Aberg JA. Reply to Monroe and Brown. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014 Jun; 58(11).

Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012 Jul; 308(4).

Anthony DD, Umbleja T, Aberg JA, Kang M, Medvik K, Lederman MM, Peters MG, Koziel MJ, Overton ET. Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals. Vaccine 2011 Apr; 29(19).

Bakare N, Edwards IR, Stergachis A, Pal S, Holmes CB, Lindquist M, Duncombe C, Dodoo A, Novendstern J, Nwokike J, Kuchenbecker R, Aberg JA, Miller V, Strobos J. Global pharmacovigilance for antiretroviral drugs: overcoming contrasting priorities. PLoS medicine 2011 Jul; 8(7).

DallaPiazza M, Aberg JA. HIV counseling and testing for household members of HIV-infected individuals in Africa: should prevention programs focus on home-based rather than clinic-based outreach?. Current HIV/AIDS reports 2011 Jun; 8(2).

Engell CA, Pham VP, Holzman RS, Aberg JA. Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. ISRN gastroenterology 2011; 2011.

Fichtenbaum CJ, Evans SE, Aberg JA. High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection. AIDS (London, England) 2011 Oct; 25(16).

Malvestutto CD, Aberg JA. Management of dyslipidemia in HIV-infected patients. Clinical lipidology 2011 Aug; 6(4).

Mehta SA, Silvera R, Bernstein K, Holzman RS, Aberg JA, Daskalakis DC. Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City. Sexually transmitted infections 2011 Jun; 87(4).

Overton ET, Sungkanuparph S, Klebert M, Royal M, Demarco-Shaw D, Powderly WG, Aberg JA. GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. The open virology journal 2011; 5.

Squires KE, Hodder SL, Feinberg J, Bridge DA, Abrams S, Storfer SP, Aberg JA. Health needs of HIV-infected women in the United States: insights from the women living positive survey. AIDS patient care and STDs 2011 May; 25(5).

Aberg JA, Ribaudo H. Cardiac risk: not so simple. The Journal of infectious diseases 2010 Feb; 201(3).

Fichtenbaum CJ, Yeh TM, Evans SR, Aberg JA. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. Journal of clinical lipidology; 4(4).

Grant PM, Aberg JA, Zolopa AR. Concerns regarding a randomized study of the timing of antiretroviral therapy in zimbabweans with AIDS and acute cryptococcal meningitis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010 Oct; 51(8).

Horberg MA, Aberg JA, Cheever LW, Renner P, O'Brien Kaleba E, Asch SM. Development of national and multiagency HIV care quality measures. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010 Sep; 51(6).

Malvestutto CD, Aberg JA. Coronary heart disease in people infected with HIV. Cleveland Clinic journal of medicine 2010 Aug; 77(8).

McComsey GA, Walker UA, Budhathoki CB, Su Z, Currier JS, Kosmiski L, Naini LG, Charles S, Medvik K, Aberg JA. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS (London, England) 2010 Oct; 24(16).

Overton ET, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, Demarco-Shaw D, Koziel MJ, Mong-Kryspin L, Sprenger HL, Yu JY, Aberg JA. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine 2010 Aug; 28(34).

Saag MS, Squires KE, Aberg JA, Bardeguez A. Letter in response to the new SHEA guideline for healthcare workers with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2010 Oct; 31(10).

Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010 Jul; 304(3).

Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, Jones L, Alston-Smith B, Rooney JF, Aberg JA. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS (London, England) 2010 Jul; 24(11).

Aberg JA. Cardiovascular complications in HIV management: past, present, and future. Journal of acquired immune deficiency syndromes (1999) 2009 Jan; 50(1).

Aberg JA. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinology and metabolism clinics of North America 2009 Mar; 38(1).

Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, Oleske JM, Currier JS, Gallant JE. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009 Sep; 49(5).

Tsibris AM, Paredes R, Chadburn A, Su Z, Henrich TJ, Krambrink A, Hughes MD, Aberg JA, Currier JS, Tashima K, Godfrey C, Greaves W, Flexner C, Skolnik PR, Wilkin TJ, Gulick RM, Kuritzkes DR. Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009 Mar; 48(5).

Aberg JA. Drug-drug interactions with newer antiretroviral agents. Topics in HIV medicine : a publication of the International AIDS Society, USA 2008 Dec; 16(5).

Gerber JG, Kitch DW, Fichtenbaum CJ, Zackin RA, Charles S, Hogg E, Acosta EP, Connick E, Wohl D, Kojic EM, Benson CA, Aberg JA. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. Journal of acquired immune deficiency syndromes (1999) 2008 Apr; 47(4).

King J, Aberg JA. Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS (London, England) 2008 Sep; 22(14).

Evans SR, Fichtenbaum CJ, Aberg JA. Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087. HIV clinical trials; 8(1).

Johnson RM, Ristig MB, Overton ET, Lisker-Melman M, Cummings OW, Aberg JA. Safety and tolerability of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV(+) individuals. HIV clinical trials; 8(3).

Tungsiripat M, Drechsler H, Aberg JA. Discontinuation of antiretroviral therapy postpartum: no evidence for altered viral set point. Journal of acquired immune deficiency syndromes (1999) 2007 Jan; 44(1).

Aberg JA. Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review. Topics in HIV medicine : a publication of the International AIDS Society, USA; 14(4).

Aberg JA. The changing face of HIV care: common things really are common. Annals of internal medicine 2006 Sep; 145(6).

Aberg JA, Rosenkranz SL, Fichtenbaum CJ, Alston BL, Brobst SW, Segal Y, Gerber JG. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS (London, England) 2006 Mar; 20(5).

Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, Baddley JW, Barron MA, Belzberg H, Boucher HW, Boyce TG, Casadevall A, Chandrasekar PH, Cleary JD, Cordonnier C, Cornely OA, Cuenca-Estrella M, Daly JS, Daoura N, Denning DW, dePauw B, de Repentigny L, Dignani MC, Dismukes WE, Donnelly JP, Donowitz GR, Dupont B, Drusano G, Ellis M, Espinel-Ingroff A, Fishman JA, Fleming R, Forrest G, Ghannoum M, Goldman M, Grazziutti M, Greene JN, Greenberg RN, Gubbins PO, Hadley S, Herbrecht R, Hiemenz JW, Hope W, Hospenthal DR, Husain S, Ito JI, Jacobson RM, Johnson M, Keating MR, Kett DH, Knapp K, Kontoyiannis DP, Krcmery VC, Larsen R, Laverdiere M, Ljungman P, Lortholary O, Maertens J, Marriott D, Mattiuzzi G, McGinnis MR, Morris M, Nucci M, Odds FC, Pankey GA, Patterson T, Pfaller M, Razonable RR, Reboli AC, Rinaldi MG, Roberts GD, Rodriguez Tudela JL, Rotstein C, Ruhnke M, Schuster M, Shoham S, Sia IG, Siebel N, Silviera F, Singh N, Sobel J, Solomkin JS, Sorrell TC, Steinbach WJ, Temesgen Z, Tortorano A, Vartivarian S, VerWeij P, Viscoli C, Viviani MA, Walker RC, Wheat JL, Wiley J, Williamson P, Wingard JR, Yu VL, Zaoutis T. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006 Oct; 43(8).

Cespedes MS, Aberg JA. Neuropsychiatric complications of antiretroviral therapy. Drug safety : an international journal of medical toxicology and drug experience 2006; 29(10).

Dubé MP, Wu JW, Aberg JA, Deeg MA, Alston-Smith BL, McGovern ME, Lee D, Shriver SL, Martinez AI, Greenwald M, Stein JH. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antiviral therapy 2006; 11(8).

Faulhaber J, Aberg JA, Puthawala K, Addrizzo-Harris D. A tale of two fungi in a person with HIV. MedGenMed : Medscape general medicine 2006; 8(4).

Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, Glesby MJ, Torriani FJ, Yang Y, Owens SI, Fichtenbaum CJ. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS research and human retroviruses 2005 Sep; 21(9).

Cespedes MS, Aberg JA. Cardiovascular and Endothelial Disease in HIV Infection. Current infectious disease reports 2005 Jul; 7(4).

Daskalakis D, Aberg JA. Case files from the Bellevue Hospital Center at New York University--lipoatrophy following long-term antiretroviral therapy. MedGenMed : Medscape general medicine 2005; 7(4).

Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, Brobst SW, Segal Y, Aberg JA. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. Journal of acquired immune deficiency syndromes (1999) 2005 Jul; 39(3).

Glesby MJ, Aberg JA, Kendall MA, Fichtenbaum CJ, Hafner R, Hall S, Grosskopf N, Zolopa AR, Gerber JG. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clinical pharmacology and therapeutics 2005 Aug; 78(2).

Larsen RA, Pappas PG, Perfect J, Aberg JA, Casadevall A, Cloud GA, James R, Filler S, Dismukes WE. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrobial agents and chemotherapy 2005 Mar; 49(3).

Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005 Oct; 41(7).

Tungsiripat M, Aberg JA. Dyslipidemia in HIV patients. Cleveland Clinic journal of medicine 2005 Dec; 72(12).

Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, Currier JS, Stone VE, Kaplan JE. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004 Sep; 39(5).

Goldman M, Zackin R, Fichtenbaum CJ, Skiest DJ, Koletar SL, Hafner R, Wheat LJ, Nyangweso PM, Yiannoutsos CT, Schnizlein-Bick CT, Owens S, Aberg JA. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004 May; 38(10).

Mussini C, Pezzotti P, Miró JM, Martinez E, de Quiros JC, Cinque P, Borghi V, Bedini A, Domingo P, Cahn P, Bossi P, de Luca A, d'Arminio Monforte A, Nelson M, Nwokolo N, Helou S, Negroni R, Jacchetti G, Antinori S, Lazzarin A, Cossarizza A, Esposito R, Antinori A, Aberg JA. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004 Feb; 38(4).

Ristig MB, Tebas P, Gandy I, Qaqish R, Aberg JA. Cure of acute hepatitis C in HIV co-infection?. Journal of clinical gastroenterology 2004 Mar; 38(3).

Aberg JA. Cardiovascular risk among HIV-positive patients on antiretroviral therapy. Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2003 Sep; 2 Suppl 2.

Aberg JA. Pulmonary cryptococcosis in normal hosts: treat or observe?. Chest 2003 Dec; 124(6).

Aberg JA, Williams PL, Liu T, Lederman HM, Hafner R, Torriani FJ, Lennox JL, Dube MP, MacGregor RR, Currier JS. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team. The Journal of infectious diseases 2003 Apr; 187(7).

Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Annals of internal medicine 2003 Aug; 139(4).

Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003 Sep; 37(5).

Juethner SN, Seyfried W, Aberg JA. Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse. HIV clinical trials; 4(3).

Juethner SN, Williamson C, Ristig MB, Tebas P, Seyfried W, Aberg JA. Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women. Journal of acquired immune deficiency syndromes (1999) 2003 Feb; 32(2).

Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA, Blaschke TF. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clinical pharmacology and therapeutics 2003 May; 73(5).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Aberg during 2013 and/or 2014. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting:

  • Janssen Scientific Affairs, LLC

Scientific Advisory Board:

  • AbbVie Inc.; Amgen Inc.; Merck & Co., Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

17 East 102 Street Floor 8 Room 241
New York, NY 10029

Tel: 212-241-6741

Address

Annenberg Building Floor 23 Room 60 B
1468 Madison Avenue
New York, NY 10029